Canada markets close in 40 minutes

Appili Therapeutics Inc. (APLIF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.02790.0000 (0.00%)
As of 09:53AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.0279
Open0.0279
BidN/A x N/A
AskN/A x N/A
Day's Range0.0279 - 0.0279
52 Week Range0.0160 - 0.0760
Volume725
Avg. Volume233,748
Market Cap3.54M
Beta (5Y Monthly)1.15
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters

    UPDATE 2-Canada's Appili gets US FDA approval for oral antibiotic solution

    The U.S. Food and Drug Administration (FDA) on Monday approved Canadian drugmaker Appili Therapeutics' liquid oral form of antibiotic drug metronidazole, offering an alternative to patients who have difficulty taking injections or pills. An injectable form of the drug, which is commonly used in the treatment of bacterial and parasitic infections, has been in shortage in the United States since early last year due to high demand and regulatory delays. Appili said its partner, privately-held Saptalis, will sell the newly approved form of the drug under the brand name Likmez in the United States.

  • Baystreet

    Stocks in play: Appili Therapeutics Inc.

    Has entered into a definitive agreement with respect to an unsecured $300,000 bridge loan from Bloom ...

  • Simply Wall St.

    Appili Therapeutics Full Year 2023 Earnings: CA$0.081 loss per share (vs CA$0.38 loss in FY 2022)

    Appili Therapeutics ( TSE:APLI ) Full Year 2023 Results Key Financial Results Revenue: CA$334.2k (down 76% from FY...